Skip to content
preclinicalWeight Loss & Diabetes

Cholecystokinin

Also known as: CCK, CCK-8, Pancreozymin, CCK-33

Cholecystokinin (CCK) is a peptide hormone and neurotransmitter found in the gut and brain that serves as the primary satiety signal terminating meals. CCK-8 (the bioactive octapeptide) and CCK-33 (the 33-amino-acid form) stimulate gallbladder contraction, pancreatic enzyme secretion, and vagal afferent satiety signaling. In the brain, CCK modulates anxiety, pain, memory, and dopamine release. CCK receptor antagonists have been explored for appetite disorders, anxiety, and pancreatic cancer.

4 cited references·5 researched benefits

Quick Answer

Cholecystokinin (CCK) is a gut-brain peptide hormone that is the primary short-term satiety signal in humans. Released from intestinal I-cells after meals, it contracts the gallbladder, stimulates pancreatic enzymes, slows gastric emptying, and signals fullness through vagal afferents to the brainstem. Brain CCK modulates anxiety and pain. Its two receptors (CCK-A in gut, CCK-B in brain) are drug targets for appetite disorders, anxiety, and gastrointestinal conditions.

Key Facts

Mechanism
CCK is released from intestinal I-cells in response to dietary fat and protein. It acts through two GPCRs: CCK-A receptor (primarily peripheral — gallbladder, pancreas, vagal afferents) and CCK-B receptor (primarily central — brain anxiety/pain circuits, identical to gastrin receptor). Peripheral CCK-A activation stimulates gallbladder contraction (bile release for fat digestion), pancreatic acinar cell enzyme secretion (lipase, amylase, trypsin), and gastric emptying delay. Vagal afferent CCK-A activation transmits satiety signals to the nucleus tractus solitarius. Central CCK-B activation in the amygdala and cortex modulates anxiety, panic, and pain processing.
Research Status
preclinical
Half-Life
~2–3 minutes
Molecular Formula
C₄₉H₆₂N₁₀O₁₆S₂
Primary Use
Weight Loss & Diabetes
Table of Contents

Benefits

  • Satiety signaling — primary short-term meal-termination signal, reducing food intake by 20–30% when administered before mealsstrong
  • Digestive function — essential for coordinated gallbladder, pancreatic, and gastric function during digestionstrong
  • Obesity research target — understanding CCK satiety pathways informs weight loss drug developmentmoderate
  • Pain modulation — CCK-B antagonists enhance opioid analgesia by blocking CCK's anti-opioid effectsmoderate
  • Gallbladder diagnostic — CCK-8 (sincalide) is FDA-approved for gallbladder function testing (ejection fraction)strong

Dosage Protocols

RouteDosage RangeFrequencyNotes
Intravenous (sincalide — CCK-8 diagnostic)0.02 mcg/kgSingle doseFDA-approved as sincalide (Kinevac) for hepatobiliary imaging. Administered IV over 30–60 seconds during HIDA scan to assess gallbladder ejection fraction. Not used therapeutically for satiety or weight loss.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Abdominal cramping — CCK stimulates smooth muscle contraction in the GI tractcommon
  • Nausea — gastric motility changes can cause nausea, especially at higher dosescommon
  • Anxiety/panic — CCK-4 (a tetrapeptide fragment) reliably induces panic attacks in susceptible individuals (used in panic research)serious
  • Biliary colic — in patients with gallstones, CCK can trigger gallbladder pain by forcing contraction against obstructing stonesserious

Frequently Asked Questions

Why can't CCK be used as a weight loss drug?
Despite being a potent satiety signal, CCK has not succeeded as an obesity treatment for several reasons: (1) extremely short half-life (~2–3 minutes) would require continuous infusion; (2) tachyphylaxis — chronic CCK exposure leads to receptor desensitization and loss of satiety effect; (3) CCK reduces meal size but not meal frequency, so total daily intake may not decrease significantly; (4) compensatory increases in hunger-promoting signals (ghrelin, NPY) offset CCK's effects. GLP-1 RAs have proven far more effective for sustained weight loss.
How does CCK-4 induce panic attacks?
CCK-4 (Trp-Met-Asp-Phe-NH₂) is a synthetic tetrapeptide that selectively activates CCK-B receptors in the brain, particularly in the amygdala and periaqueductal gray. Intravenous CCK-4 (25–50 mcg bolus) reliably induces panic attacks in 50–70% of panic disorder patients and 15–25% of healthy volunteers within 30–60 seconds. This CCK-4 challenge test is used in research to study panic disorder neurobiology and evaluate potential anxiolytic drugs. The panic response involves activation of the fear circuit, including autonomic arousal, derealization, and overwhelming dread.
What is the sincalide (Kinevac) test?
Sincalide is the C-terminal octapeptide of CCK (CCK-8) used as a diagnostic agent. During hepatobiliary scintigraphy (HIDA scan), sincalide is injected IV to contract the gallbladder. The gallbladder ejection fraction (GBEF) is calculated — values below 35–40% suggest gallbladder dyskinesia and may support cholecystectomy. This test helps diagnose acalculous gallbladder disease (symptoms without gallstones). It's one of the few direct clinical applications of a gut neuropeptide.
How does CCK interact with opioid pain relief?
CCK acts as an endogenous anti-opioid peptide. When opioids are administered, CCK release increases in the brain, partially counteracting opioid analgesia — this is one mechanism of opioid tolerance. CCK-B receptor antagonists (like proglumide) have been shown to enhance morphine analgesia and reduce tolerance development in preclinical studies. This suggests that CCK antagonism could be combined with opioids to improve pain control while reducing dose requirements, though clinical development has been limited.

References

  1. 1
    Cholecystokinin and satiety: from basic science to clinical applications(2000)PubMed ↗
  2. 2
    CCK-4-induced panic attacks in healthy volunteers: a model for studying panic disorder(2004)PubMed ↗
  3. 3
    Gut hormones and appetite regulation: role of CCK, GLP-1, and PYY(2007)PubMed ↗
  4. 4
    Cholecystokinin as an anti-opioid peptide: implications for pain and addiction(1997)PubMed ↗

Latest Research

Last updated: 2026-02-19